← All companies

Remix Therapeutics

Healthcare & Life Sci

Company overview

Remix Therapeutics develops small molecule therapeutics that modulate RNA processing. Its REMaster Platform is a proprietary drug discovery platform for designing small molecules that control RNA processing. REM-422, its lead program, is an investigational first-in-class small molecule mRNA degrader that targets the pre-mRNA of MYB. The company is headquartered in Watertown, Massachusetts.

Remix Therapeutics is private. In June 2026 it announced a merger with Passage Bio, alongside a $100 million private placement.

Industry
Healthcare & Life Sci
Headquarters
United States

Filters

Create your account

Create an account to save jobs and track applications.